|
|
|
By BIO-IT World
 Forrester Research's senior healthcare analyst, Michael Barrett, is a highly regarded consultant on technology for clinical trials. Here, he shares some thoughts on electronic data capture with Mark Uehling.
Q: Some major companies claim all new trials are using EDC. Is this true?
A: If the firms had reframed their announcements and said, 'The new default position is that we do EDC — unless circumstances indicate otherwise,' they would have been right on the money. That's what they're really doing. They're saying, 'It's EDC, unless ...' That's a helluva lot different than their saying, 'It's paper, unless ...' That's a huge change.
Q: So EDC is here to stay?
A: Two-thirds of the top 12 companies are over the hump and have made the basic strategic decision to buy in. How they're going to implement it is another story. But make no mistake: The watershed moment has been reached.
Q: Why do you think large pharmaceutical companies are more innovative than small biotech companies?
A: Big Pharma has enough trials so that e-clinical solutions offer economies of scale. Big Pharma is leading the way in IT innovation. Small biotechs are just getting their toes into the water. They outsource trials because they have so few.
Q: How do contract research organizations fit into the story?
A: They feel the most threat. They deploy the warm bodies into the field, visiting doctors' offices every six weeks on behalf of drug firms. They aren't quite sure when they want to [reduce] those staffs and go electronic. The CROs are bruised and gun-shy at the very moment that Big Pharma is finally interested in moving. The CROs are now meshing their [EDC] worldview nicely with their smaller customers and losing credibility with their larger customers.
Q: What do you make of the FDA trying to clarify or renounce IT-related aspects of 21 CFR Part 11?
A: What we're seeing now are major public policy turnarounds focused explicitly on the FDA's not wishing to impede the adoption of technology in clinical trials. The FDA was persuaded by the parties it regulates that it had over-reached. You are seeing the ducks line up for the advance of clinical technology, whether it's clinical trials data capture or clinical care patient documents.
Q: Are the sponsors of clinical trials happy with the EDC vendor community?
A: Now, finally, Big Pharma believes in the solution and in many cases decides that the homegrown alternative is the best. That's kind of weird. IT — building and running IT solutions — isn't normally a Big Pharma core competency.
Q: So drug companies believe they can find drugs and write code?!
A: There are now power centers in these companies devoted to IT. These departments are fighting for their jobs. If they home-built a solution 10 years ago that's showing age, outsourcing it may not be appetizing. It may be threatening. The vendors have left themselves open to the [pharma] IT shops saying to their colleagues, 'Stick with us. We can do it.'
PHOTO OF MICHAEL BARRETT BY DANFURNESS/FAYFOTO
Back to Data Rapture?
|
“Storage for Science – Methods for Managing Large and Rapidly Growing Data Stores in Life Science Research Environments” sponsored by Isilon
Large and rapidly growing stores of file-based and other data are a hallmark of life science research and bioinformatics. Determining how best to manage those data stores has become a significant challenge for Researchers and IT Pros alike.
This paper is intended to:
- Provide guidance on the many storage requirements common to Life Science research;
- Explain the evolution of modern storage architectures;
- Summarize the major data storage architectures currently in use.
Additionally, it will present the Isilon IQ clustered storage product as a strong and flexible solution to those needs. Download now
| |  Next-Generation Technologies Revolutionizing Oncology and Diagnostics
underwritten by Definiens
This “Briefing On” collection of Bio-IT World features, commentaries and analysis, presents some of the latest thinking on high-throughput technologies that are being applied to the fields of research and drug discovery, with particular emphasis on oncology, diagnostics and imaging technologies. Download now at no charge compliments of the underwriting sponsor, Definiens. Download This Free Paper
| |
.png "metaminer image(1)")
MetaMiner™ Cystic Fibrosis Report, Sponsored by GeneGo
This paper discusses the MetaMiner™ (CF) data analysis platform for a broad range of CF researchers designed to: 1. Easily assemble important biological and chemical experimental data available today in cystic fibrosis research. 2. Visualize key mechanisms leading to the disease through pathway maps and network models 3. Provide the CF community a “one stop shop” tool for uploading and analyzing experimental data in a disease-centered interface. Download now
|
Storage for Science
Methods for Managing Large and Rapidly Growing Data Stores in Life Science Research Environments
Sponsored by Isilon
Large and rapidly growing stores of file-based and other data are a hallmark of life science research and bioinformatics environments. Determining how best to manage those data stores has become a significant challenge for the Researchers and IT Professionals that support them.
This webcast is intended to:
More Podcasts
Isilon Systems ~ Senior Marketing Communications Manager
Isilon Systems is the worldwide leader in clustered storage systems and software for digital content and unstructured data. We seek an experienced marketing communications professional/writer expert in creating and delivering effective and persuasive business communications. The ideal candidate can think at the strategic and conceptual level and act, simultaneously, as a highly-effective and productive individual contributor. The position is based in Seattle, WA. For additional information click here: Lilly Singapore Center for Drug Discovery (LSCDD) - Associate Director of Informatics
Lead and mentor a strong team for the Bioinformatics group at the Integrative Computational Sciences (ICS) department at LSCDD towards the development of novel algorithms, data analysis methods and software tools for drug discovery. Work closely with the Software Engineering group at ICS, and collaborate with the Discovery IT organization in Europe and USA. For additional information, or to apply visit: LSCDD
|
|
|